AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10911579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 236
Study 10911579 — intervention group
Group type: COMPARATOR
Intervention: Nonaspirin group
Number of subjects: 236
Study 8615243 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-weighted fast spin-echo imaging with fat suppression
Number of subjects: 177
Study 8615243 — intervention group
Group type: COMPARATOR
Intervention: T2-weighted fast spin-echo imaging without fat suppression
Number of subjects: 177
Study 8615243 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-weighted fast spin-echo imaging with and without fat suppression
Number of subjects: 177
Study 1632174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac 75 mg over 60 min, followed by an infusion of 5 mg/h for 15 h, then 50 mg every 8 h orally
Number of subjects: 20
Study 1632174 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion and dextropropoxyfen per os
Number of subjects: 20
Study 1632174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac infusion of 75 mg over 15 min (one or two bolus infusions)
Number of subjects: 20
Study 6235099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Novum 1/35 (O/N)
Number of subjects: 26
Study 6235099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovcon 35 (OV)
Number of subjects: 26
Study 6235099 — intervention group
Group type: COMPARATOR
Intervention: Nordette (N)
Number of subjects: 26
Study 6235099 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel (1-Ng)
Number of subjects: 26
Study 6235099 — intervention group
Group type: COMPARATOR
Intervention: 1-Ng and ethinylestradiol combination
Number of subjects: 26
Study 31675083 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group (lottery-based incentive tied to daily self-weighing)
Number of subjects: 258
Study 31675083 — intervention group
Group type: COMPARATOR
Intervention: Control group (weekly messages)
Number of subjects: 258
Study 29716551 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in physical checkup examination
Number of subjects: 1463
Study 29716551 — intervention group
Group type: COMPARATOR
Intervention: Non-participation in community activities
Number of subjects: 1463
Study 29716551 — intervention group
Group type: EXPERIMENTAL
Intervention: Health consciousness and smoking status
Number of subjects: 1463
Study 29716551 — intervention group
Group type: EXPERIMENTAL
Intervention: IADL and physical functioning scores
Number of subjects: 1463
Study 26558731 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 40
Study 26558731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24751780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention sites
Number of subjects: 0
Study 22215481 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Management System (remote daily weight monitoring, daily feedback, customized information, proprietary algorithm)
Number of subjects: 0
Study 21629525 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 30
Study 21629525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18090280 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (100 mg, 200 mg, 400 mg, or 600 mg twice daily)
Number of subjects: 0
Study 18090280 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 0
Study 18090280 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 0
Study 15591732 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer fissure sealant placed on primary molars (n=241)
Number of subjects: 508
Study 15591732 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n=267)
Number of subjects: 508
Study 12757221 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid dipstick assay for S. typhi-specific immunoglobulin M
Number of subjects: 473
Study 12757221 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dipstick assay and culture
Number of subjects: 473
Study 12757221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick assay
Number of subjects: 473
Study 12757221 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture
Number of subjects: 473
Study 9927098 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide and albuterol sulfate
Number of subjects: 357
Study 9927098 — intervention group
Group type: COMPARATOR
Intervention: Albuterol base alone (control)
Number of subjects: 357
Study 7485698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 46‐2717 (CS protein) and Ro 46‐2924 (MSA‐2) vaccines at low (20 micrograms) and high (100 micrograms) doses
Number of subjects: 33
Study 7485698 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alum alone)
Number of subjects: 33
Study 7485698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 46‐2717 and Ro 46‐2924 vaccines (after third immunization)
Number of subjects: 33
Study 1967720 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U over 5 min)
Number of subjects: 128
Study 1967720 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (1.5 MU over 1 h)
Number of subjects: 128
Study 7388852 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with lignocaine, procainamide, and practolol
Number of subjects: 6
Study 7388852 — intervention group
Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 6
Study 7388852 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 6
Study 7388852 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 6
Study 31613055 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs) therapy (2 intravenous doses of 2×10^8 cells every 3 months)
Number of subjects: 20
Study 31613055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31613055 — intervention group
Group type: COMPARATOR
Intervention: Both groups (MSCs and placebo)
Number of subjects: 20
Study 31415378 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose, 1 μg/kg for 10 minutes and continuous infusion, 0.4 μg/kg/hr)
Number of subjects: 126
Study 25708562 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ligation of the inferior mesenteric artery with apical lymph node dissection
Number of subjects: 57
Study 25708562 — intervention group
Group type: COMPARATOR
Intervention: High ligation of the inferior mesenteric artery
Number of subjects: 57
Study 25708562 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ligation with apical lymph node dissection
Number of subjects: 57
Study 25708562 — intervention group
Group type: COMPARATOR
Intervention: High ligation
Number of subjects: 57
Study 25708562 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomotic leakage
Number of subjects: 57
Study 25854015 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80
Study 25854015 — intervention group
Group type: COMPARATOR
Intervention: Western medication (Fluoxetine)
Number of subjects: 80
Study 22827882 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic catheter
Number of subjects: 0
Study 22827882 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl chloride catheter
Number of subjects: 0
Study 21454742 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS (1.5 mg/mL, total 12.0 mg)
Number of subjects: 277
Study 21454742 — intervention group
Group type: COMPARATOR
Intervention: SOC (standard of care)
Number of subjects: 277
Study 21454742 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS
Number of subjects: 277
Study 21454742 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 277
Study 19428843 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV9
Number of subjects: 0
Study 19428843 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV9 alone
Number of subjects: 0
Study 19428843 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib‐PCV9‐MnCC
Number of subjects: 0
Study 19428843 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV9, PCV9‐MnCC, Hib‐PCV9‐MnCC
Number of subjects: 0
Study 19428843 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions of PCV9, MnCC and Hib
Number of subjects: 0
Study 16800837 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly ibandronate plus patient support programme (PSP)
Number of subjects: 1054
Study 16800837 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly alendronate
Number of subjects: 1054
Study 15090625 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (400 to 500 mg of dietary calcium/d supplemented with placebo)
Number of subjects: 32
Study 15090625 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium diet (standard diet supplemented with 800 mg of calcium/d)
Number of subjects: 32
Study 15090625 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dairy diet (1200 to 1300 mg of dietary calcium/d supplemented with placebo)
Number of subjects: 32
Study 15090625 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium diet
Number of subjects: 32
Study 15090625 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dairy diet
Number of subjects: 32
Study 15090625 — intervention group
Group type: COMPARATOR
Intervention: Low-calcium diet
Number of subjects: 32
Study 11003743 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte filtration using Pall BC1B filter (group F, 15 patients)
Number of subjects: 32
Study 11003743 — intervention group
Group type: COMPARATOR
Intervention: Dummy filters (group C, 17 patients)
Number of subjects: 32
Study 9380804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (M1)
Number of subjects: 27
Study 9380804 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections of three insulins (M2)
Number of subjects: 27
Study 9380804 — intervention group
Group type: EXPERIMENTAL
Intervention: Euclamin 20 mg + intermediate insulin (M3)
Number of subjects: 27
Study 9380804 — intervention group
Group type: EXPERIMENTAL
Intervention: Euclamine 20 mg + intermediate insulin (M4)
Number of subjects: 27
Study 8453961 — intervention group
Group type: EXPERIMENTAL
Intervention: rac-felodipine
Number of subjects: 12
Study 8453961 — intervention group
Group type: EXPERIMENTAL
Intervention: rac-nitrendipine
Number of subjects: 12
Study 8453961 — intervention group
Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 12
Study 3792524 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support services (special counseling sessions)
Number of subjects: 0
Study 3792524 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic support services (follow-up phone calls)
Number of subjects: 0
Study 3792524 — intervention group
Group type: COMPARATOR
Intervention: Regular clinic services (control group)
Number of subjects: 0
Study 3792524 — intervention group
Group type: EXPERIMENTAL
Intervention: Special support services (combined)
Number of subjects: 0
Study 3792524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative pregnancy rate
Number of subjects: 0
Study 31346789 — intervention group
Group type: EXPERIMENTAL
Intervention: Football training and dietary advice (FD)
Number of subjects: 50
Study 28766976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 2840
Study 28766976 — intervention group
Group type: COMPARATOR
Intervention: Alternative treatments
Number of subjects: 2840
Study 27366831 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0
Study 27366831 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 27366831 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-scopolamine response in MDD patients
Number of subjects: 0
Study 24770471 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction
Number of subjects: 42
Study 24770471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training
Number of subjects: 42
Study 24770471 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 21992869 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief telephone intervention plus treatment as usual
Number of subjects: 62
Study 21992869 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 62
Study 20890622 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Talk Intervention (FTI)
Number of subjects: 149
Study 20890622 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Talk about the Children (LT)
Number of subjects: 149
Study 17126974 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 22
Study 17126974 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine (6-21 mg/day)
Number of subjects: 22
Study 16375203 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg, 3 times daily)
Number of subjects: 30
Study 16375203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12015629 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (46 +/- 1 g) during the run (M+C)
Number of subjects: 8
Study 12015629 — intervention group
Group type: COMPARATOR
Intervention: Water during the run (M + W)
Number of subjects: 8
Study 12015629 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (M+C)
Number of subjects: 8
Study 12015629 — intervention group
Group type: COMPARATOR
Intervention: Water (M + W)
Number of subjects: 8
Study 9801011 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention
Number of subjects: 5887
Study 7642836 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg
Number of subjects: 28
Study 7642836 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg
Number of subjects: 28
Study 7642836 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.9 mg/kg
Number of subjects: 28
Study 7642836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2666335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (I.V.) metronidazole
Number of subjects: 154
Study 2666335 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (I.V.) metronidazole-gentamicin-ampicillin
Number of subjects: 154
Study 812456 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative parenteral hyperalimentation
Number of subjects: 44
Study 812456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 31520209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with a 50-kV x-ray
Number of subjects: 434
Study 31520209 — intervention group
Group type: COMPARATOR
Intervention: IORT cancellation
Number of subjects: 434
Study 26846656 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion gap exceeded extension gap by 2.5 mm (Group 1)
Number of subjects: 404
Study 26846656 — intervention group
Group type: COMPARATOR
Intervention: Flexion gap equal to extension gap (Group 2)
Number of subjects: 404
Study 25400202 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing the task from a category-learning task to choosing the 'winning' object in each stimulus
Number of subjects: 0
Study 25400202 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Who's winning' effect
Number of subjects: 0
Study 25400202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intersection discovery process
Number of subjects: 0
Study 23395257 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.25 μg twice daily
Number of subjects: 61
Study 23395257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 21434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized group (RHA)
Number of subjects: 50
Study 21434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference group (RHA)
Number of subjects: 50
Study 18607835 — intervention group
Group type: EXPERIMENTAL
Intervention: Pellicle-covered samples
Number of subjects: 10
Study 18607835 — intervention group
Group type: COMPARATOR
Intervention: Pellicle-free samples (Control)
Number of subjects: 10
Study 15780700 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance comorbidity
Number of subjects: 328
Study 15780700 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety comorbidity
Number of subjects: 328
Study 15780700 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined comorbidity
Number of subjects: 328
Study 15780700 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD due to non-combat stressors
Number of subjects: 328
Study 11880840 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal morphine 20 microgram/kg
Number of subjects: 65
Study 11880840 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal morphine 10 microgram/kg
Number of subjects: 65
Study 11880840 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 65
Study 10447232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense lifestyle intervention (low-fat, high-fibre diet and regular physical exercise, one-month learning and training session)
Number of subjects: 186
Study 10447232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense lifestyle intervention
Number of subjects: 186
Study 10447232 — intervention group
Group type: COMPARATOR
Intervention: Usual care (one-hour counselling session with a specially trained nurse)
Number of subjects: 186
Study 10447232 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study 7604646 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d cetirizine
Number of subjects: 24
Study 7604646 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d cetirizine
Number of subjects: 24
Study 7604646 — intervention group
Group type: COMPARATOR
Intervention: cetirizine (10 mg/d or 20 mg/d)
Number of subjects: 24
Study 2672989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (1 ml/kg)
Number of subjects: 0
Study 2672989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% or 0.5% (Age (years +2)/10 ml per dermatome)
Number of subjects: 0
Study 2672989 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 384858 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days of treatment with trimethoprim/sulfamethoxazole
Number of subjects: 38
Study 384858 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of treatment with trimethoprim/sulfamethoxazole
Number of subjects: 38
Study 30967640 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) 3 hours after LCBDE
Number of subjects: 100
Study 30967640 — intervention group
Group type: COMPARATOR
Intervention: Traditional management with regular diet when tolerated (Control group)
Number of subjects: 100
Study 26606421 — intervention group
Group type: COMPARATOR
Intervention: Community-based intervention
Number of subjects: 5879
Study 26606421 — intervention group
Group type: COMPARATOR
Intervention: Higher level of education
Number of subjects: 5879
Study 26606421 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-height ratio
Number of subjects: 5879
Study 26606421 — intervention group
Group type: EXPERIMENTAL
Intervention: Being divorced/widowed compared with married
Number of subjects: 5879
Study 26606421 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip circumference
Number of subjects: 5879
Study 26606421 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 5879
Study 26001844 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle coaching plus care coordination
Number of subjects: 450
Study 26001844 — intervention group
Group type: COMPARATOR
Intervention: Care coordination alone
Number of subjects: 450
Study 26001844 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 450
Study 23637831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit juice consumption
Number of subjects: 618
Study 23637831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit juice consumption in low-median intake of total polyphenols
Number of subjects: 618
Study 21263010 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI)
Number of subjects: 601
Study 21263010 — intervention group
Group type: COMPARATOR
Intervention: Reboxetine (NARI)
Number of subjects: 601
Study 19737501 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption with nonprimary partners
Number of subjects: 1419
Study 19737501 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption with primary partners
Number of subjects: 1419
Study 19737501 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner substance use (both partners drinking)
Number of subjects: 1419
Study 16280464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus sufferers
Number of subjects: 0
Study 16280464 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 15262734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg 3 times per day with levodopa placebo (n = 151)
Number of subjects: 301
Study 15262734 — intervention group
Group type: COMPARATOR
Intervention: Levodopa 25/100 mg carbidopa/levodopa 3 times per day with pramipexole placebo (n = 150)
Number of subjects: 301
Study 11959050 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 463
Study 11959050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study 10346418 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms twice daily
Number of subjects: 482
Study 10346418 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 micrograms
Number of subjects: 482
Study 7621634 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 g human intravenous immunoglobulin (IVIg) every three weeks
Number of subjects: 42
Study 7621634 — intervention group
Group type: COMPARATOR
Intervention: Human albumin placebo every three weeks
Number of subjects: 42
Study 2238755 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatin (6 x 2 capsules, 6 x 300 mg/d)
Number of subjects: 10
Study 2238755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 347878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol
Number of subjects: 25
Study 30224341 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI-Bevacizumab
Number of subjects: 376
Study 30224341 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6-Bevacizumab
Number of subjects: 376